Index trend and stocks in action September 18, 2017

Nifty opened with a gap-down and traded southwards in the first half of the session. North Korea’s missile test over Japan on Friday dragged Asian markets followed by India. Europe too opened on a negative note, however, markets attempted recovery in the second half majorly driven by IT sector that closed almost a per cent up. Ultimately, markets ended flat keeping weak bias of 587 advances and 862 declines on NSE. Technically, Nifty took a major support at 38.2 per cent retracement level of the prior upward rally near 10,050 levels and bounced back. However, Nifty could not break previous high and retreated yet again to close flat. Hence, if on intraday basis, Nifty continues to head upwards we hold 10,115-10,138 as the immediate resistances followed by 10,180-10,200. However, if Nifty retreats from the current prices, we hold 10,040-10,020 as the immediate support followed by 9,970 levels.

Dixon Technologies: Listing of equity shares of Dixon Technologies. 

Bharat Road Network: Listing of equity shares of Bharat Road Network. 

Dr Reddy’s Laboratories: The Audit of API Mirfield Plant, United Kingdom, by the US FDA, has been completed. Form 483 with three observations has been issued. 

Piramal Enterprises: The Meeting of Administrative Committee of the Board of Directors of the company approved the allotment of 2,000 secured redeemable Non-Convertible Debentures (NCD’s) having Face value of Rs 10,00,000 each aggregating to Rs 200 crores on private placement basis. 

Mahanagar Gas: Mahanagar Gas started Piped Natural Gas (PNG) supply in Dombivili (East) area of Maharashtra.

Wipro: Wipro and Hewlett Packard Enterprise to Deliver Enterprise Hybrid Cloud Solution Based on HPE ProLiant for Microsoft Azure Stack. 

Laurus Labs:  Laurus Labs receives the EIR from USFDA, and also successfully completes the German Regulatory Authority for Unit 2 and WHO inspections for Units 1 & 3.

Balrampur Chini Mills: Company has approved investment of Rs 175 crore in education sector, in tranches, over a period of 5 years. 

Mangalam Drugs and Organics: Company has received final approval from WHO for the drug Emtricitabine.

Asian Granito: The Company is pleased to announce the launch of its new product range of GVT in Grestek with brand name MARBLEX. 

Cadila Healthcare: Zydus' Nesher Pharmaceuticals gets USFDA final approval for Oseltamivir Powder for Oral Suspension'.